Ratings by Jefferies (Dennis Ding)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/20/2026 | NewAmsterdam Pharma Co NV | NAMS | Maintain | Buy (N/A) |
|
Details | ||
| 7/13/2026 | Kardigan Inc | KARD | New Coverage | Buy (N/A) |
24.45 (19.60) |
-19.84% | Details | |
| 7/7/2026 | Crinetics | CRNX | Downgrade | Hold (Buy) |
42.03 (84.95) |
102.12% | Details | |
| 6/1/2026 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Hold (N/A) |
|
Details | ||
| 5/1/2026 | Esperion Therapeutics | ESPR | Downgrade | Hold (Buy) |
2.00 (3.18) |
59% | Details | |
| 4/30/2026 | Indivior | INDV | Maintain | Buy (N/A) |
|
Details | ||
| 4/20/2026 | Amphastar Pharmaceuticals | AMPH | Downgrade | Hold (Buy) |
22.88 (22.96) |
0.35% | Details | |
| 4/7/2026 | Teva Pharma | TEVA | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2026 | ANI Pharmaceuticals | ANIP | Maintain | Buy (N/A) |
|
Details | ||
| 3/25/2026 | Teva Pharma | TEVA | Maintain | Buy (N/A) |
|
Details | ||
| 3/19/2026 | Olema Pharmaceuticals | OLMA | New Coverage | Buy (N/A) |
15.05 (10.56) |
-29.83% | Details | |
| 3/13/2026 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Hold (N/A) |
|
Details | ||
| 3/3/2026 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2026 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2026 | SpyGlass Pharma | SGP | New Coverage | Buy (N/A) |
26.73 (26.86) |
0.49% | Details | |
| 1/22/2026 | Amicus Therapeutics | FOLD | Downgrade | Hold (Buy) |
14.31 (14.49) |
1.26% | Details | |
| 12/29/2025 | Inhibikase Therapeutics Inc | IKT | Maintain | Buy (N/A) |
|
Details | ||
| 12/10/2025 | Assembly Biosciences | ASMB | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2025 | Milestone Pharmaceuticals | MIST | Maintain | Hold (N/A) |
|
Details | ||
| 9/3/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Hold (N/A) |
|
Details | ||
| 8/18/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Hold (N/A) |
|
Details | ||
| 7/22/2025 | Indivior | INDV | New Coverage | Buy (N/A) |
16.01 (34.56) |
115.87% | Details | |
| 7/14/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Hold (N/A) |
|
Details | ||
| 6/11/2025 | Mineralys Therapeutics, Inc. | MLYS | New Coverage | Hold (N/A) |
16.19 (25.57) |
57.94% | Details | |
| 6/5/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 6/2/2025 | Lyra Therapeutics | LYRA | Maintain | Hold (N/A) |
|
Details | ||
| 3/3/2025 | Immunovant | IMVT | New Coverage | Hold (N/A) |
20.25 (39.90) |
97.04% | Details | |
| 1/21/2025 | Crinetics | CRNX | Upgrade | Buy (Hold) |
37.35 (42.03) |
12.53% | Details | |
| 12/31/2024 | Rhythm Pharmaceuticals | RYTM | New Coverage | Buy (N/A) |
56.34 (104.74) |
85.91% | Details | |
| 11/20/2024 | Ardelyx, Inc | ARDX | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2024 | Inhibikase Therapeutics Inc | IKT | New Coverage | Buy (N/A) |
2.69 (2.38) |
-11.52% | Details | |
| 9/20/2024 | Assembly Biosciences | ASMB | Upgrade | Buy (Hold) |
18.17 (35.18) |
93.62% | Details | |
| 9/6/2024 | Amicus Therapeutics | FOLD | New Coverage | Buy (N/A) |
11.52 (14.31) |
24.22% | Details | |
| 9/3/2024 | Recursion Pharmaceuticals | RXRX | Maintain | Hold (N/A) |
|
Details | ||
| 7/17/2024 | Veru, Inc. | VERU | Maintain | Hold (N/A) |
|
Details | ||
| 7/9/2024 | Recursion Pharmaceuticals | RXRX | New Coverage | Hold (N/A) |
7.40 (3.33) |
-55% | Details | |
| 5/7/2024 | Lyra Therapeutics | LYRA | Downgrade | Hold (Buy) |
4.03 (0.50) |
-87.59% | Details | |
| 9/27/2023 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 6/27/2023 | Cara Therapeutics | CARA | Maintain | Buy (N/A) |
|
Details | ||
| 6/20/2023 | Milestone Pharmaceuticals | MIST | Downgrade | Hold (Buy) |
3.74 (1.14) |
-69.52% | Details | |
| 6/7/2023 | Veru, Inc. | VERU | Upgrade | Hold (Underperform) |
1.06 (2.69) |
153.77% | Details | |
| 5/30/2023 | Cara Therapeutics | CARA | New Coverage | Buy (N/A) |
3.28 (5.32) |
62.2% | Details | |
| 5/30/2023 | Lyra Therapeutics | LYRA | New Coverage | Buy (N/A) |
2.43 (0.50) |
-79.42% | Details | |
| 5/30/2023 | Ardelyx, Inc | ARDX | New Coverage | Buy (N/A) |
3.29 (3.76) |
14.29% | Details | |
| 4/3/2023 | Pardes Biosciences | PRDS | Downgrade | Hold (N/A) |
1.32 (2.16) |
63.64% | Details | |
| 2/24/2023 | Esperion Therapeutics | ESPR | New Coverage | Buy (N/A) |
5.83 (2.00) |
-65.69% | Details | |
| 2/15/2023 | Corcept Therapeutics | CORT | Downgrade | Hold (Buy) |
23.06 (113.38) |
391.67% | Details | |
| 12/19/2022 | NewAmsterdam Pharma Co NV | NAMS | New Coverage | Buy (Buy) |
12.00 (24.92) |
107.67% | Details | |
| 10/17/2022 | NGM Biopharmaceuticals | NGM | Downgrade | Hold (Buy) |
11.55 (1.54) |
-86.67% | Details | |
| 8/8/2022 | Cincor Pharma Inc | CINC | Maintain | Buy (N/A) |
|
Details | ||
| 7/27/2022 | Corcept Therapeutics | CORT | New Coverage | Buy (N/A) |
26.81 (113.38) |
322.9% | Details | |
| 7/20/2022 | NGM Biopharmaceuticals | NGM | New Coverage | Buy (N/A) |
15.01 (1.54) |
-89.74% | Details | |
| 2/2/2022 | Arbutus Biopharma | ABUS | Upgrade | Buy (Hold) |
2.81 (5.09) |
81.14% | Details | |
| 2/1/2022 | Cincor Pharma Inc | CINC | New Coverage | Buy (N/A) |
18.11 (29.06) |
60.46% | Details | |
| 1/18/2022 | Pardes Biosciences | PRDS | New Coverage | Buy (N/A) |
13.95 (2.16) |
-84.52% | Details | |
| 12/29/2021 | Arbutus Biopharma | ABUS | New Coverage | Hold (N/A) |
3.86 (5.09) |
31.87% | Details | |
| 11/30/2021 | Sigilon Therapeutics | SGTX | Downgrade | Hold (Buy) |
3.77 (22.47) |
496.02% | Details | |
| 10/26/2021 | Roivant Sciences | ROIV | New Coverage | Buy (N/A) |
7.04 (34.52) |
390.34% | Details |
